SeraCare Life Sciences Inc.
EU clears J&J’s $21B Synthes buyout | Wall Street Beat
Johnson & Johnson‘s (NYSE:JNJ) move to ditch its DePuy trauma business mollified EuroZone anti-trust regulators enough to win their approval for its $21.3 billion buyout of Synthes Inc.
Piper Jaffray: Abiomed wins reimbursement code | Wall Street Beat
Abiomed (NSDQ:ABMD) is slated to win a reimbursement code for procedures involving its Impella heart pump, according to analysts at Piper Jaffray.
In a summary of recent editorial panel decisions, the American Medical Assn. revealed that the panel approved the Society for Cardiovascular Angiography and Interventions’ proposal for the reimbursement code, according to theflyonthewall.com.
“Exit hangover” casts a pall on private equity | Wall Street Beat
Private equity players are in for some stiff competition this year, as large-cap PE shops invade the middle-market space, according to a report from PE stalwart Bain & Co.
The company’s Global PE Report details a huge “exit overhang” – more aptly deemed an “exit hangover” by PE Hub’s Jonathan Marino – as PE-backed companies seek exits.
And the mega-deals of the past 10 years or so are a thing of the past, according the report, as detailed by Marino.
Moody’s raises Boston Scientific rating again | Wall Street Beat
Ortho stocks up on strong Q2 prelims for Biomet | Earnings Roundup
Shares of orthopedic device makers are up this morning after bellwether Biomet Inc. reported preliminary sales numbers indicating 3.8% growth for its fiscal second quarter.
SeraCare leaves it options open for a buyout
SeraCare Life Sciences Inc.’s (NSDQ:SRLS) board of directors began exploring "strategic alternatives for the company to enhance shareholder value," which includes a possible sale of the company.
"SeraCare has not made a decision to pursue any specific transaction or other strategic alternative, so there can be no assurance that the exploration of strategic alternatives will result in a sale of the Company or in any other transaction," according to SEC filings.
SeraCare CEO replaced amid “disappointing” 60 percent dip in earnings
SeraCare Life Sciences Inc. (NSDQ:SRLS) CEO Susan Vogt was replaced by CFO Greg Gould amid a troubling third quarter earnings report and a hostile takeover bid by private equity firm MSMB Capital.
Private equity and med-tech M&A: Where there’s smoke there’s barbarians?
Last week, the world’s largest private-equity company quietly put its money on the table in what could turn out to be a very big gambling chip in the world of medical device mergers & acquisitions.
In a quarterly earnings announcement, The Blackstone Group (NYSE:BX) confirmed a startlingly large $16.1 billion leveraged-buyout fund, which is about 10 percent of the $159 billion total assets the firm has under management.
Neoprobe launches European branch amid U.S. boondoggle
Cancer diagnostics company Neoprobe Corp. (NYSE Amex:NEOP) announced today that it established a European business unit tasked with development and commercialization in the European Union.
The move underscores the Dublin, Ohio-based company’s focus on international commercialization of its flagship Lymphoseek radiopharmaceutical, a diagnostic tracing agent for detecting and treating certain types of cancer.
SeraCare girds for $82 million hostile takeover | Acquisitions roundup
SeraCare Life Sciences Inc. (NSDQ:SRLS) is poised for a $82 million buyout by private equity firm MSMB Capital, which offered to acquire for $4.25 per share.
The offer represents a 22 percent premium over the stock’s closing price on June 22 at $3.49. The stock closed at $4.11 yesterday.
MSMB specializes in strategic long-term investments in health care and biotechnology and has been an investor in SeraCare for some time.
